Vascular-Bed-Specific Hemostasis and Hypercoagulable States: Clinical Utility of Activation Peptide Assays in Predicting Thrombotic Events in Different Clinical Populations

Robert D. Rosenberg

doi:10.1055/s-0037-1616199

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 86(01): 41-50
DOI: 10.1055/s-0037-1616199

Research Article

Schattauer GmbH

Vascular-Bed-Specific Hemostasis and Hypercoagulable States: Clinical Utility of Activation Peptide Assays in Predicting Thrombotic Events in Different Clinical Populations

Robert D. Rosenberg

¹Department of Medicine, Division of Molecular Medicine and Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston; and the Department of Biology, Massachusetts Institute of Technology, Cambridge

› Author Affiliations

Abstract

Summary

This chapter summarizes the new paradigm for arterial thrombosis. This new paradigm emphasizes the heterogeneity of endothelial cells and the signaling pathways that control endothelial cell gene expression in surrounding tissue. It is suggested that genetic alterations in the signaling pathways are probably responsible for localized thrombosis, as manifested by heart attacks and strokes. A discussion of two clinical studies supporting the new arterial thrombosis paradigm is also included in this chapter. These studies, carried out by genetic engineering in mice, employ activation peptides to help predict the occurrence of thrombotic events in humans.

Key words

Activation peptides - arterial thrombosis - vascular beds - tissue factor - hypercoagulability

Full Text

References

References
1 Mann K, Edelberg JM, Rosenberg RD. Blood Coagulation in Cardiovascular Disease. In: Molecular Basis of Heart Disease. A Companion to Braunwald’s Heart Disease. Chien KR, Breslow JL, Leiden JM, Rosenberg RD, Seidman C, Braunwald E. eds. Philadelphia: WB. Saunders; 1999: 505-36.
2 Nemerson Y, Giesen PL. Some thoughts about localization and expression of tissue factor. Blood Coagul Fibrinolysis 1988; 1: S45-7.
3 Lorand L. Sol Sherry lecture in thrombosis: research on clot stablization provides clues for improving thrombolytic therapies. Arterioscler Thromb Vasc Biol 2000; 20: 2-9.
4 Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984; 74: 1-6.
5 Gayle RB, Maliszewski CR, Gimpel SD, Schoenborn MA, Gaspary RG, Richards C. et al. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest 1998; 101: 1851-9.
6 Deguchi H, Takeya H, Urano H, Gabazza EC, Zhou H, Suzuki K. Adenosine regulates tissue factor expression on endothelial cells. Thromb Res 1998; 2: 57-64.
7 Enjyoji K, Sévigny J, Lin Y, Frenette PS, Christie PD, Schulte AM. et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nature Med 1999; 5: 1010-7.
8 Lui CY, Sobel JH, Weitz JI, Kaplan KL, Nossel HL. Immunologic identification of the cleavage products from the A alpha- and B beta-chains in the early stages of plasmin digestion of fibrinogen. Thromb Haemost 1986; 56: 100-6.
9 Rosenberg RD, Aird WC. Thrombosis. In: Molecular Cardiovascular Medicine. Haber E. ed. New York: Scientific American; 1995: 115-32.
10 Greaves M, Preston FE. The hypercoagulable state in clinical practice. Br J Haematol 1991; 79: 148-51.
11 Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med 1993; 119: 819-27.
12 Macik BG, Ortel TL. Clinical and laboratory evaluation of the hypercoagulable states. Clin Chest Med 1995; 16: 375-87.
13 Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126: 638-44.
14 De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-44.
15 Rosenberg RD, Aird WC. Vascular bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555-64.
16 Boyer C, Wolf M, Vedrenne J, Meyer D, Larrieu MJ. Homozygous variant of antithrombin III: AT III Fontainebleau. Thromb Haemost 1986; 56: 18-22.
17 Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58: 1094.
18 Chowdhury V, Lane DA, Mille B, Auberger K, Gandenberger-Bachem S, Pabinger I. et al. Homozygous antithrombin deficiency: report of two new cases (99Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 198-202.
19 Okajima K, Ueyama H, Hashimoto Y, Sasaki Y, Matsumoto K, Okabe H. et al. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto. Thromb Haemost 1989; 61: 20-4.
20 Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-7.
21 Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127: 895-903.
22 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT. et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
23 Dilawari JB, Bambery P, Chawla Y, Kaur U, Bhusnurmath SR, Malhotra HS. et al. Hepatic outflow obstruction (Budd-Chiari syndrome): experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994; 73: 21-36.
24 Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-8.
25 Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C. et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factos. French Society of Haematology. Lancet 1996; 348: 573-7.
26 Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J. et al. The “primary“ antiphospholipid antibody syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 366-74.
27 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
28 Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC. et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-6.
29 Comp PC, Elrod JP, Karzenski S. Warfarin-induced skin necrosis. Semin Thromb Hemost 1990; 16: 293-8.
30 Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine (Baltimore) 1981; 60: 413-28.
31 Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohisto-chemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985; 38: 469-79.
32 Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996; 56: 191-207.
33 Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555-64.
34 Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986; 67: 362-5.
35 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88: 1346-53.
36 Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996; 97: 2440-51.
37 Aird WC, Jahroudi N, Weiler-Guettler H, Rayburn HB, Rosenberg RD. Human von Willebrand factor sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci USA 1995; 92: 4567-71.
38 Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H. et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998; 101: 1983-91.
39 Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP. et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
40 Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997; 77: 408-23.
41 Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev 1995; 75: 519-60.
42 Poppa V, Miyashiro JK, Corson MA, Berk BC. Endothelial NO synthase is increased in regenerating endothelium after denuding injury of the rat aorta. Arterioscler Thromb Vasc Biol 1998; 18: 1312-21.
43 Niebauer J, Cooke JP. Cardiovascular effects of exercise: role of endothelial shear stress. J Am Coll Cardiol 1996; 28: 1652-60.
44 Christ G, Seiffert D, Hufnagl P, Gessl A, Wojta J, Binder BR. Type 1 plasminogen activator inhibitor synthesis of endothelial cells is downregulated by smooth muscle cells. Blood 1993; 81: 1277-83.
45 Gallicchio M, Argyriou S, Ianches G, Filonzi EL, Zoellner H, Hamilton JA. et al. Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells. Arterioscler Thromb 1994; 14: 815-23.
46 Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol 1997; 138: 1117-24.
47 Everett AD, Le Cras TD, Xue C, Johns RA. eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am J Physiol 1998; 274: L1058-65.
48 Edelberg JM, Aird WC, Wu W, Rayburn H, Mamuya WS, Mercola M. et al. PDGF mediates cardiac microvascular communication. J Clin Invest 1998; 102: 837-43.
49 Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997; 89: 1224-34.
50 Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376: 70-4.
51 Schlaeger TM, Qin Y, Fujiwara Y, Magram J, Sato TN. Vascular endothelial cell lineage-specific promoter in transgenic mice. Development 1995; 121: 1089-98.
52 Schlaeger TM, Bartunkova S, Lawitts JA, Teichmann G, Risau W, Deutsch U. et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 1997; 94: 3058-63.
53 Bauer KA, Broekmans AW, Bertina RM, Conard J, Horellou MH, Samama MM, Rosenberg RD. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988; 71: 1418-26.
54 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-12.
55 Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989; 74: 2007-15.
56 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-5.
57 Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest 1987; 80: 1527-34.
58 Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Howarth DJ, Barzegar S. et al. A comparison of novel hemostatic factors and conventional risk factors for the prediction of coronary heart disease. (Submitted).
59 Miller J, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD. Haemostatic changes that constitute the hypercoagulable state [letter]. Lancet 1991; 338: 1079.
60 Ardissino D, Merlini PA, Mannucci PM, Bauer KA, Galvani M, Ottani F. et al. Thrombin generated and long-term outcome in acute coronary syndromes. (Unpublished data).
61 Edelberg JM, Aird WC, Wu W, Rayburn H, Mamuya WS, Mercola M, Rosenberg RD. PDGF mediates cardiac microvascular communication. J Clin Invest 1998; 102: 837-43.